Read our latest news, and find more about us and our portfolio companies.

Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen

Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, Inc.

Akili Completes $55 Million Financing to Advance Company’s Digital Medicine Platform and Product Pipeline Aimed at Treating Cognitive Dysfunction

Financing led by Temasek with new and existing investors including Baillie Gifford, Amgen Ventures, M Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Funds, and Brooklands Capital Strategies Proceeds will advance commercial and clinical-stage pipeline in ADHD, multiple sclerosis, and depression

Medisafe Demonstrates Double-Digit Impact on Medication Adherence in Hypertension Patients

Medisafe, the leading medication management platform released data showing that, on average, hypertensive patients increase their prescription refills by almost 10% after they start using the company's mobile app.

Macrophage Pharma Appoints Dr Michael Moore as Chairman

Macrophage Pharma Limited (‘MPL’) announced today that it has appointed Dr. Michael Moore as non-executive Chairman with immediate effect.

Merck partners with Medisafe to help improve medication adherence for Cardiometabolic Patients

Merck partners with Medisafe to help improve medication adherence for Cardiometabolic Patients

STORM Therapeutics wins Life Science Innovation Award

STORM Therapeutics today announced that it has won the Life Science Innovation Award at the Business Weekly Awards ceremony


Forendo Pharma today announces that it has been granted a €3 million R&D loan from Business Finland, for the development of a novel drug for endometriosis treatment. Business Finland is the most important public funding agency for research funding in Finland.

Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

"The sale of Prexton Therapeutics to Lundbeck is a very strong validation of our model of founding companies based on spinning-off assets from Merck KGaA, Darmstadt, Germany and managing them very actively as a shareholder. We are very excited to see the program being acquired by Lundbeck, a leading company in the field of neurology, and feel this is a strong confirmation of the investment thesis on which Prexton was founded in 2012 by Francois Conquet and us, namely that modulating mGluR4 is a highly promising therapeutic approach for the sympomatic treatment of Parkinson`s Disease and dyskinesia.", said Jasper Bos, Ph.D., Vice-President and Head of Healthcare of M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, Board Member of Prexton.

M Ventures Invests in CLEARink Displays

C Round Oversubscribed

Artios exercises option to in-license potential first-in-class nuclease development programme

Artios Pharma, a leading DNA Damage Response (DDR) company developing innovative new treatments for cancer, today announces that it has exercised its option to in-license the first nuclease drug development programme under its research collaboration and option agreement with Masaryk University in the Czech Republic. The collaboration was formed in June 2017 to discover and develop novel cancer treatments by targeting DNA nucleases involved in the DDR.

Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors

Industry leader who brings over 35 years of experience in developing successful pharmaceutical companies

STORM Therapeutics Appoints Distinguished Professor and Nobel Prize Winner Professor Thomas Cech as Scientific Advisor

STORM today announced the appointment of Nobel Prize Winner professor Thomas Cech as a Scientific Advisor

STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures

Taiho Ventures First Investment in Europe